Palvella Therapeutics Wins 2026 PACT Healthcare & Life Sciences Company of the Year Award
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
WAYNE, Pa., May 15, 2026 Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORINâ„¢ rapamycin in...
WAYNE, Pa., Feb. 24, 2026 — Palvella Therapeutics announced positive topline results from its Phase 3 SELVA clinical study...
